New ANX1502 tablet surpasses targeted blood levels in CAD trial
A new tablet formulation of Annexon Biosciences’ experimental therapy ANX1502 resulted in therapy levels in the blood that surpassed those expected to be effective in fasting participants with cold agglutinin disease (CAD). These results from a proof-of-concept study reflect a promising pharmacokinetic profile, which describes how the medication…